Trial Profile

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JANX 007 (Primary) ; Darolutamide
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; First in man
Acronyms ENGAGER-PSMA-01
Sponsors Janux Therapeutics

Most Recent Events

07 Aug 2025 According to Janux Therapeutics media release, company continues to enroll in this phase 1 clinical trial in mCRPC and look forward to additional clinical data for JANX007 expected in the second half of 2025.
08 May 2025 The protocol has been amended to addition in treatment arm.
08 May 2025 Planned number of patients changed from 105 to 272.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com